Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
Business Wire•14/10/2026•08:30 ET
0
Key Highlights
- ➤$135 million upfront and near-term preclinical milestone payments for Vir Biotechnology
- ➤$90 million upfront includes $65 million cash and $25 million equity investment
- ➤Up to $1.74 billion in development, regulatory and commercial milestones
- ➤Gilead receives exclusive license for three dual-masked T-cell engager candidates
- ➤Vir will discover and optimize candidates; Gilead handles development and commercialization
Expert Statements
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
“We believe TCEs have a powerful role to play in the future of immunotherapy to treat cancer. This collaboration with Gilead provides an opportunity to generate multiple differentiated candidates aimed at difficult-to-address solid tumors and to expand the potential impact of our science, while also advancing our own clinical oncology portfolio.”
Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology
“This transaction provides further external validation of Vir Biotechnology’s integrated discovery capabilities and the broad potential of the PRO-XTEN® platform.”
Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences
“We look forward to combining Gilead’s established and growing oncology capabilities, including our extensive development expertise and focus on next-generation immunotherapies, with Vir Biotechnology’s innovative discovery capabilities.”
Flavius Martin, MD, Executive Vice President, Research, Gilead Sciences
“Together with Vir Biotechnology, we seek to bring meaningful innovative therapeutics to patients.”
Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN(®) Dual-masked T-cell Engagers for Solid Tumors
- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN(®) masking technology with Gilead’s oncology development and commercialization expertise
Get started
Create a free account to read the full story.